Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1989 1
1991 1
1992 1
1993 5
1994 4
1995 8
1996 3
1997 8
1998 25
1999 24
2000 39
2001 54
2002 109
2003 137
2004 127
2005 129
2006 165
2007 167
2008 155
2009 179
2010 195
2011 204
2012 215
2013 194
2014 249
2015 224
2016 303
2017 323
2018 368
2019 369
2020 426
2021 462
2022 459
2023 449
2024 495
2025 551
2026 246

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,267 results

Results by year

Filters applied: . Clear all
Page 1
Imiquimod.
Skinner RB Jr. Skinner RB Jr. Dermatol Clin. 2003 Apr;21(2):291-300. doi: 10.1016/s0733-8635(02)00094-3. Dermatol Clin. 2003. PMID: 12757252 Review.
Imiquimod is the first of the immune response modifiers to stimulate a localized immune response to treat infectious skin conditions. ...Common and plantar warts respond better to imiquimod in combination with cryosurgery, occlusion, and keratolytics. Reports of suc …
Imiquimod is the first of the immune response modifiers to stimulate a localized immune response to treat infectious skin conditions. …
Imiquimod.
Garland SM. Garland SM. Curr Opin Infect Dis. 2003 Apr;16(2):85-9. doi: 10.1097/00001432-200304000-00004. Curr Opin Infect Dis. 2003. PMID: 12734440 Review.
PURPOSE OF REVIEW: Imiquimod is the first member of a new class of immune response modifiers; it was first approved in 1997 for the topical treatment of external genital and perianal warts. ...RECENT FINDINGS: Imiquimod, a patient-applied topical 5% cream is clinica …
PURPOSE OF REVIEW: Imiquimod is the first member of a new class of immune response modifiers; it was first approved in 1997 for the t …
Imiquimod: a review.
Gupta AK, Browne M, Bluhm R. Gupta AK, et al. J Cutan Med Surg. 2002 Nov-Dec;6(6):554-60. doi: 10.1007/s10227-001-0134-6. Epub 2002 Oct 9. J Cutan Med Surg. 2002. PMID: 12362256 Review.
BACKGROUND AND OBJECTIVE: Imiquimod (Aldara) is an immune response modifier used primarily to treat anogenital warts. Imiquimod induces cytokines and enhances cell-mediated cytolytic antiviral activity in vivo. ...
BACKGROUND AND OBJECTIVE: Imiquimod (Aldara) is an immune response modifier used primarily to treat anogenital warts. Imiquimod …
Imiquimod-Associated Pemphigus Foliaceus.
Farid MRA, Lugão HB, Julio TA, Donadi EA, Bueno Filho R, Roselino AM. Farid MRA, et al. Am J Ther. 2022 Nov-Dec 01;29(6):e716-e719. doi: 10.1097/MJT.0000000000001251. Epub 2020 Oct 1. Am J Ther. 2022. PMID: 33021541 No abstract available.
Toll-like receptor activation induces airway obstruction and hyperresponsiveness in guinea pigs.
Xiang Y, Liu J, Nie M, Nilsson G, Säfholm J, Adner M. Xiang Y, et al. Respir Res. 2024 Nov 29;25(1):421. doi: 10.1186/s12931-024-03050-3. Respir Res. 2024. PMID: 39614276 Free PMC article.
METHODS: The agonists poly(I: C) (TLR3), lipopolysaccharide (LPS; TLR4) and imiquimod (TLR7), or the combination of poly(I: C) and imiquimod (P/I) were administered intranasally once a day over four consecutive days. ...For the expression of inflammatory mediators, …
METHODS: The agonists poly(I: C) (TLR3), lipopolysaccharide (LPS; TLR4) and imiquimod (TLR7), or the combination of poly(I: C) and …
Imiquimod: unexpected killer.
Leverkus M. Leverkus M. J Invest Dermatol. 2004 May;122(5):XV-XVI. doi: 10.1111/j.0022-202X.2004.22537.x. J Invest Dermatol. 2004. PMID: 15140251 Free article. Review. No abstract available.
Genital warts treatment: Beyond imiquimod.
Yuan J, Ni G, Wang T, Mounsey K, Cavezza S, Pan X, Liu X. Yuan J, et al. Hum Vaccin Immunother. 2018 Jul 3;14(7):1815-1819. doi: 10.1080/21645515.2018.1445947. Epub 2018 Apr 9. Hum Vaccin Immunother. 2018. PMID: 29505317 Free PMC article. Review.
Current therapies for genital warts are mainly ablative, or alternatively topical application of imiquimod cream and sinecatechin (polyphenon E) ointment to the warts. However, low patient compliance and high recurrence rate are significant problems for the treatment of ge …
Current therapies for genital warts are mainly ablative, or alternatively topical application of imiquimod cream and sinecatechin (po …
[Imiquimod--clinical efficacy].
Beutner KR. Beutner KR. Ann Dermatol Venereol. 2000;127(10 Suppl):3S19-3S21. Ann Dermatol Venereol. 2000. PMID: 11116859 Review. French. No abstract available.
Imiquimod in dermatology: an overview.
Hanna E, Abadi R, Abbas O. Hanna E, et al. Int J Dermatol. 2016 Aug;55(8):831-44. doi: 10.1111/ijd.13235. Int J Dermatol. 2016. PMID: 27387373 Review.
Imiquimod is an immune response modifier commercially available as a 3.75 and 5% cream. Topical imiquimod stimulates the innate and adaptive immune responses and induces cytokine production. ...
Imiquimod is an immune response modifier commercially available as a 3.75 and 5% cream. Topical imiquimod stimulates the innat …
Imiquimod for Anal High Grade Intraepithelial Neoplasia: A Systematic Review.
Gallio N, Preti M, Casetta E, Albuquerque A, Vieira-Baptista P, Borella F, Bevilacqua F, Cavallero C, Mistrangelo M, Revelli A. Gallio N, et al. Curr Oncol Rep. 2025 Jul;27(7):833-843. doi: 10.1007/s11912-025-01675-1. Epub 2025 May 19. Curr Oncol Rep. 2025. PMID: 40387973 Free PMC article.
Reported complete response (CR) rates ranged between 14.3-78.6%, and 21.4-67% partial response (PR) rates of 3-weekly application for 16 weeks imiquimod course. A second course of imiquimod led to incremental response (CR 15-23.8%, PR 19-30%). ...DISCUSSION: In our …
Reported complete response (CR) rates ranged between 14.3-78.6%, and 21.4-67% partial response (PR) rates of 3-weekly application for 16 wee …
6,267 results